Private Equity
The Great Unbundling: Why Private Equity is Carving Up Europe’s Industrial Empires
Private equity firms are reshaping Europe’s economy by acquiring non-core divisions from industrial conglomerates, aiming to unlock value and create leaders.
The Great Creditor Clash: Inside the Billion-Dollar Courtroom Battle Tearing Wall Street Apart
A $1.1bn rescue deal for First Brands Group has ignited a Wall Street civil war, pitting lenders against each other in a high-stakes legal battle.
KKR’s Billion-Dollar Bet: Why This Private Equity Giant is Going All-In on India
KKR is betting big on India, committing $10 billion to tap into its growth. This deep dive explores the strategy and the forces driving this major investment.
The $850 Million Deception: How a Car Parts Giant Exposed a Deep Flaw in Modern Finance
The collapse of First Brands and an $850M fraud lawsuit reveal the dark side of working capital finance, a key tool of the modern economy.
The Unseen Threat: Are ‘Zombie’ Firms About to Haunt Private Capital for a Decade?
A top EQT exec warns of a “zombie firm” wave in private capital, unable to raise funds and stuck with old investments. What does this mean for the economy?
High-Stakes Finance Unpacked: A PE Giant’s UK Nightmare, a Shadow Banking Mystery, and a Big Pharma Showdown
A deep dive into Cinven’s UK crisis, a fintech lending mystery involving a Utah bank, and Novo Nordisk’s strategic challenge to Pfizer.
The $4 Billion Insurance Shake-Up: Why Private Capital is Targeting Brighthouse Financial
Aquarian Holdings’ potential $4bn deal to take insurer Brighthouse private signals a major shift in finance, driven by private capital’s thirst for assets.
The Billion-Dollar Revolt: Why Private Equity is Waging War on Its Most Powerful Law Firm
A revolt is brewing in private equity as investors push back against the massive legal fees of top law firm Kirkland & Ellis, signaling a major power shift.
Thermo Fisher’s $10 Billion Bet: Unpacking the Mega-Deal for Clario and the Future of Drug Development
Thermo Fisher’s potential $10B acquisition of Clario signals a major shift in the drug development landscape, blending healthcare, data, and finance.
Spain’s Tax Showdown: Why a Probe into Private Equity Giant CVC Could Redefine European Finance
A tax fraud probe into PE firm CVC threatens to upend how carried interest and holding companies are treated in Spain, with huge economic implications.
The Trillion-Dollar Blind Spot: Why Private Equity is Making a Big Bet on Women’s Health
Private equity’s profit-driven playbook meets the underserved women’s health market, creating a trillion-dollar opportunity for innovation and disruption.
Sequoia’s Seismic Split: Decoding the Fractures in Global Finance
A VC giant splits, PE floods Japan, and a nuclear deal baffles. These events signal a new, fragmented era for global finance and investing.